title: Sofosbuvir-Induced Erythrodermic Pityriasis Rubra Pilaris-Like Drug Eruption.
abstract: Until 2011, the standard-of-care therapy for patients with hepatitis C consisted of interferon and ribavirin. The recent advent of new targeted therapies against this virus has provided more options of treatment for infected patients. Sofosbuvir, a nucleotide inhibitor of hepatitis C virus (HCV) RNA polymerase, was recently approved by the US Food and Drug Administration in 2013. Various Phase 3 trials with sofosbuvir combination therapy have reported an incidence of rash between 7% and 18%. We here describe a case of sofosbuvir-induced erythrodermic pityriasis rubra pilaris-like drug eruption.
authors.forename: Evelyn J
authors.initials: EJ
authors.lastname: Cheung
authors.forename: Jaroslaw J
authors.initials: JJ
authors.lastname: Jedrych
authors.forename: Joseph C
authors.initials: JC
authors.lastname: English
mesh_terms: D000998:Antiviral Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003875:Drug Eruptions / Q000209:etiology / Q000473:pathology; D006526:Hepatitis C / Q000188:drug therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D010916:Pityriasis Rubra Pilaris / Q000139:chemically induced* / Q000473:pathology; D000069474:Sofosbuvir / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D000998:Antiviral Agents; D000069474:Sofosbuvir